ZyVersa Therapeutics Publish Paper In Angiogensis Peer-Review Journal That Demonstrated Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure And Function In Retinopathy Of Prematurity Animal Model
$ZVSA
Biotechnology: Pharmaceutical Preparations
Health Care
- Publication showed that IC 100 suppressed retinal microglia activation by interfering with ASC speck formation, attenuating retinal inflammation, abnormal retinal vascularization, and retinal thinning, and it led to restored retinal function.
- Retinopathy of Prematurity (ROP), affecting very low birth weight premature infants is a leading cause of childhood blindness worldwide.
- ZyVersa is developing Inflammasome ASC Inhibitor IC 100 to inhibit multiple types of inflammasomes and their associated ASC specks that trigger damaging inflammation and its perpetuation and spread to surrounding tissues.